Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

Engineered virus-like particles power up gene editing, correcting blindness in mice

Prime editing, a versatile form of gene editing that can correct most known disease-causing genetic mutations, now has a new vehicle to deliver its machinery

January 8, 2024

Meta Title: “Chong Kun Dang Pharmaceutical Patent: Injectable Testosterone Undecanoate for Deficiency Treatment

Share this article According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Chong

March 29, 2024

England joins Wales and Scotland in halving HPV vaccine dose – Pharmaceutical Technology

The HPV vaccine has been part of the NHS’s vaccination schedule since 2008. Now, in England, only one dose is needed for protection against the

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.